The pharmacokinetic profile of atracurium was wmim-H in six patients with acute hepatic and renal failure and compared with that in six normal patients after an i.v. bolus (mean dose 0.7mgkg~l). The plasma concentrations were measured by high pressure liquid chromatography and the data fitted to a twocompartment pharmacokinetic model. The results from the two groups were not significantly different, giving a mean plasma elimination half-life of 22 min in patients with severe hepatic and renal failure and a mean of 21 min in the normal group.
In patients (ASA 1) undergoing minor surgery the pharmacokinetic profile of atracurium besylate is concise and reproducible (Ward et al., 1983) . The relatively short elimination half-life of approximately 20 min can be explained as elimination extensively by Hof mann decomposition, a non-enzymic process which is temperature-and pH-dependent and which occurs in plasma even in vitro (Merrett, Thompson and Webb, 1983) . Animal studies in the cat (Neill and Chappie, 1982) have shown that this elimination is also essentially independent of renal or hepatic function. To investigate this latter property of atracurium in man a study was designed to compare pharmacokinetic parameters after a single i.v. bolus in a group of patients with hepatic and renal failure with those for a group of normal patients.
PATIENTS AND METHODS .
Two groups of six patients were studied. The subjects in group I, in grade IV hepatic coma (Sherlock; 1975) , were being ventilated for the respiratory failure resulting from this degree of fulminant liver failure. Subjects 1,2,3,4 and 5.were suffering from an overdose of paracetamol and subject 6 had undergone a liver transplant, which had failed, 13 days previously. The patients were in the Liver Unit at King's College Hospital and were, having charcoal column haemoperfusion and haemodialysis daily. Neither haemoperfusion nor haemodialysis was in operation during each investigation. Although each patient was primarily in hepatic failure, biochemical values (table I) showed them to be in renal failure also. The plasma pH of each was in the physiological range (approx 7.4 unit) with the exception of patient 6, in whom it was 7.25 unit. Each had an axillary temperature between 37 and 37.5°C. Subject 2 was investigated on two separate occasions with a 9-day interval. Atracurium was given as a bolus into a central vein and arterial blood samples were taken from an arteriovenous shunt.
In group II the patients, undergoing routine minor surgery, had normal renal and hepatic function. Atracurium was administered as a bolus into a hand vein and sampling was from the superior vena cava.
. The collection and analysis of samples was as described previously (Ward et al., 1983) . Heparinized blood samples (10 ml) were withdrawn at 0, 2, 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120, 150, 180 min. The plasma from each was separated rapidly and stored at -20 °C for extraction within 24 h. Unchanged atracurium concentrations were measured by high pressure liquid chromatography (Neill and Jones, 1983) .
Mean plasma concentrations against time for each patient were examined as a semi-log plot and fitted to a two-component exponential (C= Ae~" + Be~f) by the method of non-linear least squares analysis.
From the macrokinetic parameters (A, a, B, P) values for Tf (distribution half-life), Tf (elimination half-life), V t (first compartment volume), Cl (total clearance) and V TO (total distribution volume) were calculated (symbols are as described by Hull (1979) ): (table II) and group II (table III) . A comparison between group I and group II using the unpaired t test (table IV) showed no significant differences in elimination half-life (TiO and clearance, but significant increases in distribution halflife (TV") and distribution volumes. Mean values gave an elimination half-life of 22 min in group I and 21 min in group II.
DISCUSSION
This study has demonstrated that the elimination half-life of atracurium was not altered significantly by renal or hepatic failure. In renal failure (McLeod, Watson and Rawlins, 1976 ) and in hepatic failure, an increase in drug distribution volume is not unusual. In the patients in group I, sdme of whom were oedematous, it can be seen that the total clearance of drug increased as the distribution volume increased. With atracurium the elimination half-life was unaltered despite the changing distribution volumes and this can be achieved only if the clearance changes.
Three patients in group I are of special interest. Patient 2 was examined on two separate occasions (2 and 2a) and demonstrated an increase in distribution volume with a deterioration in renal and hepatic function, but no change in plasma half-life of the drug. Patient 5 was in high-output cardiac failure (cardiac output of 17 litre min" 1 : thermal dilution) and a systemic arterial pressure of 80/50 min Hg and those could account for the very high apparent total volume of distribution. Patient 6 had an increased elimination half-life. This may be because his arterial pH was 7.25 unit, thus decreasing the rate of Hofmann decomposition. Blood pH could not be maintained within the physiological range because of the severity of his condition.
Pancuronium is the non-depolarizing neuromuscular blocking drug whose phannacokinetics have been studied most extensively in patients with liver disease. In liver cirrhosis (Duvaldestin et al., 1978) and extrahepatic biliary obstruction (Westra, Vermeer et al., 1981 ) the increase in elimination half-life was explained by an increase in distribution volume. In this hospital, using pancuronium in fulminant hepatic failure, the increase in elimination half-life was attributed to a decrease in plasma clearance (Ward, Judge and Corall, 1982) . Westra, Vermeer 0.71 ± 0.08 2.9 ± 0.6 22.0 ± 4.0 7.9 ± 3.5 2.6 ± 0.9 6.5 ± 1. and colleagues (1981) noted very little change in kinetics using gallamine in liver disease, but this drug is of little value in cases with concomitant renal failure (Feldman, Cohen and Golling, 1969) . Using Org NC45 in renal failure, Fahey and colleagues (1981) stated that there was no significant difference in elimination half-life compared with a normal group. However, in a study in cats (Westra, Houwertjes et al., 1981) it was shown that an increase in bile salt concentration such as would occur in hepatic failure inhibited the hepatic clearance of pancuronium and Org NC 45.
In conclusion, a review of available literature and the results of the present study support the view that the elimination half-life of atracurium is unaffected by both renal and hepatic failure.
